MARKET

ANAB

ANAB

AnaptysBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.81
-0.95
-6.03%
Closed 16:00 09/23 EDT
OPEN
15.91
PREV CLOSE
15.76
HIGH
16.08
LOW
14.78
VOLUME
272.44K
TURNOVER
--
52 WEEK HIGH
41.02
52 WEEK LOW
10.00
MARKET CAP
404.37M
P/E (TTM)
-4.9603
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present
GlobeNewswire · 09/11 21:05
ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating AnaptysBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AnaptysBio, Inc. (NASDAQ: ANAB) on behalf of long-term stockholders. Our investigation concerns whether the board of directors of AnaptysBio
GlobeNewswire · 09/02 00:36
Shuman Glenn & Stecker Investigates AnaptysBio, Inc.
Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.
Business Wire · 08/24 14:30
How Should Investors Feel About AnaptysBio's (NASDAQ:ANAB) CEO Remuneration?
Hamza Suria has been the CEO of AnaptysBio, Inc. (NASDAQ:ANAB) since 2011, and this article will examine the...
Simply Wall St. · 08/21 14:24
AnaptysBio's lead drug fails to beat placebo in sinus inflammation study
Thinly traded micro cap AnaptysBio (ANAB -5.2%) is down, albeit on modest turnover of 42K shares, in reaction to preliminary results from a Phase 2 clinica
seekingalpha · 08/10 20:33
AnaptysBio EPS misses by $0.04
AnaptysBio (NASDAQ:ANAB): Q2 GAAP EPS of -$0.79 misses by $0.04. Cash, cash equivalents and investments of $392.2M. Press Release
seekingalpha · 08/10 17:40
AnaptysBio Says 'We plan to re-assess the etokimab program following review of the complete week 16 data from the ECLIPSE trial later this year.'
Benzinga · 08/10 12:10
AnaptysBio Reports Top-Line Data From Interim Analysis Of ECLIPSE Phase 2 Clinical Trial Of Etokimab; Says 'Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis'
Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis   Secondary analyses demonstrated NPS and blood eosinophil level
Benzinga · 08/10 12:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANAB. Analyze the recent business situations of AnaptysBio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANAB stock price target is 18.50 with a high estimate of 28.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 203
Institutional Holdings: 46.03M
% Owned: 168.58%
Shares Outstanding: 27.30M
TypeInstitutionsShares
Increased
30
2.23M
New
43
-543.97K
Decreased
45
2.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
James Topper
President/Chief Executive Officer/Director
Hamza Suria
Chief Financial Officer
Dennis Mulroy
Chief Operating Officer/General Counsel
Eric Loumeau
Other
Paul Lizzul
Lead Director/Independent Director
Hollings Renton
Independent Director
Dennis Fenton
Independent Director
Laura Hamill
Independent Director
John Schmid
Independent Director
J. Ware
Independent Director
J. Anthony Ware
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AnaptysBio Inc stock information, including NASDAQ:ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.